Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules
7 Articles
7 Articles
Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules
Biotechnology firm Enodia Therapeutics has announced a research collaboration and licensing agreement with pharma giant Pfizer to discover and develop small molecule inhibitors of Sec61, using Enodia’s proprietary platform. Under the terms of the agreement, Enodia will perform discovery activities to screen, optimize, and develop Sec61 inhibitor candidates against multiple collaboration targets. Following the collaboration term, Pfizer will be …
PARIS–(BUSINESS WIRE)– Enodia Therapeutics, a biotechnology company developing novel small molecule-based therapies for targeted protein degradation at the point of synthesis, announced today that it has entered into a research collaboration and licensing agreement with Pfizer Inc. for the discovery and development of Sec61 inhibitors. The collaboration is aimed at accelerating the discovery and […]
Enodia lands $500M Pfizer deal to target proteins at the point of synthesis - European Biotechnology Magazine
Paris-based Enodia Therapeutics is entering a partnership with big pharma Pfizer to discover and develop small molecules for targeted protein degradation at the point of synthesis with a deal that could potentially bring more than $500 million (€446 million) to the biotech company.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
